Related Experiment Videos
Pharmacotherapy of dyslipidemia
1School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, USA. jmckenney@ncrinc.net
Insights
Lowering low-density-lipoprotein cholesterol (LDL-C) is crucial for reducing coronary heart disease (CHD) risk. Statins are primary treatments, but combination therapy may be needed for severe hyperlipidemia.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Elevated low-density-lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease (CHD).
- Despite established guidelines, achieving target LDL-C levels remains a challenge for many hypercholesterolemic patients.
- Drug therapy is often necessary to reach target LDL-C levels.
Purpose of the Study:
- To review the different types of dyslipidemia.
- To assess the most effective pharmacological treatments for hyperlipidemia.
- To emphasize the importance of LDL-C reduction in preventing CHD events.
Main Methods:
- Review of current literature on dyslipidemia management.
- Assessment of lipid-lowering drug classes including statins, fibrates, niacin, and resins.
- Evaluation of treatment efficacy based on lipid-lowering abilities, safety, and tolerability.
Main Results:
- Statins are the first-line pharmacotherapeutic agents due to their efficacy in lowering LDL-C and reducing CHD events and mortality.
- Statin monotherapy is effective for moderate hypertriglyceridemia with elevated LDL-C.
- Fibrates or niacin are indicated for severe hypertriglyceridemia, while resins offer an alternative for isolated hypercholesterolemia or specific patient groups.
Conclusions:
- Achieving target LDL-C levels is essential for CHD risk reduction in hypercholesterolemic patients.
- Statins are the cornerstone of lipid-lowering therapy.
- Combination drug therapy may be required for severe or refractory hyperlipidemia.
Abstract:
Reducing elevated levels of low-density-lipoprotein cholesterol (LDL-C) significantly reduces the incidence of coronary heart disease (CHD) events and mortality in hypercholesterolemic patients. CHD risk reduction is proportional to LDL-C reduction. Despite this knowledge, many physicians are not applying existing treatment guidelines to the extent required to achieve target LDL-C levels. Target LDL-C levels are not achievable for most patients without drug therapy. Based on their lipid-lowering abilities, safety, and tolerability profiles, the HMG-CoA reductase inhibitors (statins) are the first-line pharmacotherapeutic agents for hypercholesterolemia. The ability of statins to reduce CHD events and total mortality in primary- and secondary-prevention patients also supports this assertion. For combined dyslipidemia, statin monotherapy is a reasonable initial approach in patients with moderate hypertriglyceridemia because statins effectively lower both LDL-C and triglycerides. Fibrates or niacin are effective therapies for severe hypertriglyceridemia. Resins are moderately effective in isolated hypercholesterolemia, and are a useful alternative to statins in pregnant women or patients with liver disease. For severe hyperlipidemia that does not respond to single drug therapy, combination drug therapy may be required. This article reviews the various manifestations of dyslipidemia and assesses the most efficacious treatments.